Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06526065
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-23
Brief Title:
Molecular Mechanisms in Malignant Lymphoma- Predict MMML Predict
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Molecular Mechanisms in Malignant Lymphoma- Predict
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The trial aims at the construction and validation of an accurate affordable and simple prognostic tool to be used in everyday clinical practice which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP-like first-line therapy
Detailed Description:
Observational study of 500 recruited and 300 evaluable patients with de novo large cell B Cell lymphoma age 18-80 Standard guideline recommended treatment by treating physicians discretion Collection of clinical data PET-CT data liquid biopsy WGSequencing to determine optimal prognostic factors to surpass prediction offered by current IPI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None